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ORIGINAL ARTICLE
Phase II Trial of Paclitaxel, Carboplatin, and Topotecan with
G-CSF Support in Previously Untreated Patients with
Extensive Stage Small Cell Lung Cancer: Southwest
Oncology Group 9914
Paul J. Hesketh, MD,* Jason McCoy, MS,† Frank R. Dunphy II, MD,‡ James D. Bearden III, MD,§
Geoffrey R. Weiss, MD, Jeffrey K. Giguere, MD,¶ James N. Atkins, MD,# Shaker R. Dakhil, MD,**
Karen Kelly, MD,‡‡# John J. Crowley, PhD,† and David R. Gandara, MD††
Purpose: This phase II study (S9914) evaluated the efficacy and
toxicity of the three-drug combination of paclitaxel, carboplatin, and
topotecan with granulocyte colony–stimulating factor support in previ-
ously untreated patients with extensive stage small cell lung cancer.
Patients and Methods: Patients with newly diagnosed extensive
stage small cell lung cancer received topotecan 1.0 mg/m2 intrave-
nously on days 1 through 4; paclitaxel 175 mg/m2 intravenously on
day 4, and carboplatin AUC  5 intravenously on day 4, treatments
were repeated every 21 days for a maximum of six cycles. All
patients also received granulocyte colony–stimulating factor 5 g/
kg/day beginning on day 5 of each cycle.
Results: A total of 88 patients were enrolled on the study; 79
patients were assessable for survival and toxicity and 74 patients for
response. Objective response was observed in 50 patients (68%;
95% confidence interval [CI]: 56%–78%) with nine patients (12%)
achieving a complete response. Median progression-free survival
was 7 months (95% CI: 6–8 months) and median overall survival
was 12 months (95% CI: 11–14 months). The 1- and 2-year survival
rates were 48% (95% CI: 37%–59%) and 20% (95% CI: 11%–29%),
respectively. The most common toxicities were hematologic. Grade
3 and 4 neutropenia was noted in 17 (22%) and 27 (34%) patients,
respectively. Febrile neutropenia developed in only four patients.
Two patients (3%) died of treatment-related causes.
Conclusion: The combination of paclitaxel, carboplatin, and topo-
tecan combined with granulocyte colony–stimulating factor support
is an active and reasonably well-tolerated regimen for the treatment
of extensive stage small cell lung cancer.
Key Words: Small cell lung cancer, chemotherapy, phase II trial.
(J Thorac Oncol. 2006;1: 991–995)
Small cell lung cancer (SCLC) comprises approximately15% to 20% of the estimated 175,500 new cases of lung
cancer that will be diagnosed in the United States in 2006.1,2
Approximately one third of new SCLC cases will present
with disease limited to a single hemithorax and have a small
chance of long-term disease control with combined modality
therapy.3 The two thirds of patients presenting with more
extensive disease remain incurable with available treatment
options. The current standard of care for patients with exten-
sive stage SCLC (ES-SCLC) and a good performance status
is four to six cycles of cisplatin or carboplatin combined with
etoposide or irinotecan.4–7 Despite high initial rates of re-
sponse to treatment, the median survival for patients receiv-
ing such therapy is approximately 9 to 10 months and ranges
from 9 to 13 months. New treatment approaches are urgently
needed for this disease.
Paclitaxel inhibits cell replication by stabilization of mi-
crotubules. It has useful activity in a broad spectrum of malig-
nancies. Two single-agent trials using paclitaxel in chemother-
apy-naive patients have been conducted in SCLC.8,9 The Eastern
Cooperative Oncology Group and the North Central Cancer
Treatment Group noted response rates of 34% (11/32 patients)
and 53% (23/43 patients), respectively, in their phase II trials.
Leukopenia was the major toxicity in both studies.
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Topotecan, a topoisomerase I inhibitor, is a well-estab-
lished treatment for patients with recurrent SCLC.10 It pene-
trates well into all tissues including the central nervous
system. Topotecan has also demonstrated significant activity
as a single agent in previously untreated patients with ES-
SCLC. Schiller et al.,11 employing a schedule of 2.0 mg/m2/day
for 5 days, noted a 39% response rate in 48 patients with
ES-SCLC. The first 13 patients were treated without a colo-
ny-stimulating factor (CSF); the next 35 received 5 g/kg of
granulocyte CSF (G-CSF) for 10 to 14 days starting on day 6.
Median survival time was 10 months. The 1-year survival
rate was 39%. The major toxicity was grade 3 or 4 neutro-
penia in 92% of patients treated without G-CSF, compared
with 29% who received G-CSF. Limited experience with the
combination of topotecan and paclitaxel demonstrated en-
couraging activity for this novel combination in SCLC. A
small phase II trial of topotecan and paclitaxel combined with
G-CSF as initial therapy for 32 patients with ES-SCLC
achieved an overall response rate of 69% and median survival
of 12.5 months.12 Given the single-agent activity of both
paclitaxel and topotecan and their encouraging activity in
combination in ES-SCLC, a logical approach would be to
combine both agents with a platinum compound for use in
previously untreated patients.
St. Louis University conducted a phase I study of
topotecan combined with carboplatin and paclitaxel.13 Pa-
tients received carboplatin at a dose-calculated area under the
curve (AUC) of 5.0 to 6.0 day 1, paclitaxel 175 mg/m2 over
1 hour day 1, and topotecan 0.5 to 1.25 mg/m2/day for 4 to 5
days. The impact of sequence was evaluated by switching the
next course of carboplatin and paclitaxel administration to
day 4 or 5. Fifty-one patients with solid tumors at all sites
were entered. Partial response was observed in 33%. Dose-
limiting toxicity (DLT) for the early sequence was 50% grade
3 and 4 neutropenia in patients at doses of paclitaxel, carbo-
platin, and topotecan (TCT) of 175 mg/m2, AUC  5, and
0.75 mg/m2/day, respectively. The DLT for the late sequence
was 50% grade 3 and 4 neutropenia in patients at TCT of 175
mg/m2, AUC  5 and 1.0 mg/m2/day, respectively. After the
addition of G-CSF, neutropenia was reduced to 10%.
Thrombocytopenia, anemia, and nonhematologic toxicity
were not dose limiting. Based on toxicity data, the recom-
mended respective doses of TCT for further phase II testing
were late sequence 175 mg/m2, AUC  5, and 0.75 mg/m2/
day for 5 days without G-CSF or 175 mg/m2, AUC  5, and
1.0 mg/m2/day for 4 days with G-CSF. Based on this expe-
rience, a multi-institutional trial employing the 4-day late
sequence of TCT with G-CSF support was conducted by the
Southwest Oncology Group (SWOG) in previously untreated
patients with ES-SCLC.
PATIENTS AND METHODS
Eligibility
Patients were required to have histologically or cyto-
logically confirmed newly diagnosed ES-SCLC. Limited
stage disease was considered to be disease confined to one
hemithorax, mediastinal, hilar, or supraclavicular area that
could be encompassed within a single radiation port. Exten-
sion of disease beyond the areas defined for limited disease
was considered ES. All patients were required to have mea-
surable or assessable disease documented by computed to-
mography, magnetic resonance imaging, radiography, phys-
ical examination, or nuclear examination; be 18 years of age
and older; have a performance status of 0–2; and have
acceptable hepatic, cardiac, hematologic, and renal function
as documented by a serum creatinine less than or equal to the
institutional upper limit of normal and calculated creatinine
clearance 50 ml/min. Patients with brain metastases were
only eligible if the brain metastases were controlled (without
symptoms or treated with radiation and/or surgery). No pre-
vious systemic chemotherapy or biologic or radiation therapy
for SCLC was allowed. The study was approved by the
institutional review boards of the respective institutions, and
all patients gave written informed consent.
Treatment Plan
Patients received paclitaxel 175 mg/m2 intravenously
(IV) over 1 hour on day 4; carboplatin AUC  5 over 1 hour
IV on day 4, and topotecan 1.0 mg/m2 IV over 30 minutes
days 1 to 4. Treatment was repeated every 21 days for a
maximum of six cycles. Patients also received G-CSF 5
g/kg/day by subcutaneous injection beginning on day 5 of
each cycle. G-CSF was continued until the post-nadir abso-
lute granulocyte count was 10,000/l. All patients were
premedicated for paclitaxel hypersensitivity with dexameth-
asone, diphenhydramine, and ranitidine or cimetidine. Appro-
priate antiemetic regimens containing a 5-hydroxytryptamine
antagonist were recommended for all patients. Treatment at
the time of disease recurrence or progression after six cycles
was at the discretion of the individual investigator.
Dose Modifications
Patients experiencing a nadir granulocyte count of
500/l or a nadir platelet count of 50,000 or requiring a
2-week delay in hematologic recovery were required to un-
dergo a dose reduction of all three agents (dose level 1:
paclitaxel 150 mg/m2, carboplatin AUC 4.5, and topotecan
0.75 mg/m2; dose level 2: paclitaxel 135 mg/m2, carboplatin
AUC  4.0, and topotecan 0.50 mg/m2). Patients experienc-
ing grade 2 neurologic toxicity had a dose reduction of
paclitaxel. Dose modifications for other toxicities were spec-
ified in the protocol. Patients who required longer than a
2-week delay in treatment or a third dose reduction were
removed from the study.
Response and Toxicity Criteria
Standard SWOG criteria were used for response deter-
mination.14 Time to progression was calculated from the date
of entry into study to the date of documentation of progres-
sion or death (in the absence of progression). Survival was
calculated from the date of entry into study until the date of
death. Both intervals were determined using the Kaplan-
Meier method. Toxicity grading was done according to the
Common Toxicity Criteria, version 2.0.15 Complete blood
counts were obtained pre-study and then weekly throughout
the study. Serum creatinine, bilirubin, serum glutamate oxaloa-
cetate transaminase, and serum glutamate pyruvate transaminase
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were obtained before cycle 1 and thereafter on the first day of
each cycle. Criteria for removal of patients from the study
included progression of disease, unacceptable toxicity as
determined by the treating physician in consultation with the
study coordinator, a delay in treatment of longer than 2
weeks, more than two dose reductions in any drug, or patient
refusal.
Statistical Considerations
The main objective of the study was to test whether the
combination of paclitaxel, carboplatin, and topotecan plus
G-CSF has promise in terms of increasing survival and
response rates in patients with extensive disease SCLC. The
regimen would be considered promising if the true median
survival from registration were 13.5 months and would be
considered of no further interest if the true median survival
were 9 months. A critical value of 11.5 months median
survival would be sufficient to rule against the null hypothesis
of 9 months in favor of the alternative of 13.5 months. With
75 patients accrued over 18 months, an additional 1 year of
follow-up and assuming exponential survival, the power of a
one-sided 0.05 level test of 9- versus 13.5-month survival is
0.90. Response rates (confirmed plus unconfirmed, complete
and partial) and rates of specific toxicities can be estimated to
within at worst 11% (95% confidence interval) with 75
patients. Any toxicity occurring with at least 5% probability
is likely to be seen with 75 patients at least once (97.9%
chance).
Overall and progression-free survival were determined
based on the method of Kaplan and Meier.16 Confidence
intervals for the median overall and progression-free survival
were calculated according to the method of Brookmeyer and
Crowley.17
RESULTS
Patient Characteristics
Between October of 1999 and June of 2001, 88 patients
were registered in the study. Seven patients were ineligible
because measurable disease was not assessed within 28 days
before registration (two patients), elevated serum glutamate
oxaloacetate transaminase (one patient), complete blood
count not performed before registration (one patient), pallia-
tive radiotherapy received before starting treatment (one
patient), inadequate renal function (one patient), and inade-
quate baseline information (one patient). Two additional
patients never received any protocol treatment and are not
analyzable for any endpoint. The remaining 79 patients were
eligible and assessable for survival and toxicity. Their char-
acteristics are displayed in Table 1. The median age was 61.6
(range, 43–79), and a majority of patients (58%) were male.
Most patients had a performance status of 0–1, but eight
patients (10 %) had a performance status of 2.
Toxicity
Seventy-nine patients are assessable for toxicity. Grade
3 and 4 toxicities are detailed in Table 2. The most common
toxicities were hematologic. Grade 3 and 4 neutropenia was
noted in 17 (22%) and 27 patients (34%), respectively.
Febrile neutropenia developed in only four (5%) patients,
however. Red blood cell and platelet transfusions were re-
quired in 33 (42%) and 11 patients (14%), respectively.
Severe nonhematologic toxicities were relatively infrequent.
Grade 3 or 4 fatigue, hyponatremia, nausea, and vomiting
were noted in nine (11%), eight (10%), eight (10%), and nine
patients (11%), respectively. No grade 4 neuropathy was
noted. Grade 2 (not shown) and grade 3 sensory neuropathy
developed in eight (10%) and six (8%) patients, respectively.
Two patients (3%) died of treatment-related causes. One
patient died of a respiratory infection without neutropenia,
and one patient died of infection with grade 3–4 neutropenia.
Fifty-one patients (65%) completed all six cycles of
treatment. Nine patients (11%) discontinued treatment be-
cause of toxicity and 19 patients were removed from the
study for progressive disease (11 patients), death (three pa-
tients), or other reasons (five patients).
Response and Survival
Objective response to treatment is displayed in Table 3.
Seventy-four patients are assessable for response. An objec-
tive response was observed in 50 patients (68%; 95% CI:
56%–78%) with nine patients (12%) achieving a complete
response. Progressive disease or early death was noted in six
patients (8%). The median progression-free survival was 7
months (95% CI: 6–8 months) and median overall survival
TABLE 1. Patient Characteristics (n  79)
Variable No. of Patients %
Median age, yr (range) 61.6 (43–79)
Male:female 46:33 58:42
PS 0–1:2 71:8 90:10
Metastatic sites
Single 20 25
Multiple 58 73
Disease status
Measurable 75 95
Nonmeasurable 4 5
PS, performance status.
TABLE 2. Grade 3 and 4 Toxicity (n  79)
Adverse Effect
Grade 3 Grade 4
No. of Pts. % No. of Pts. %
Hematologic
Neutropenia 17 22 27 34
Thrombocytopenia 38 48 3 4
Anemia 15 19 0 0
Nonhematologic
Fatigue 6 8 3 4
Hyponatremia 6 8 2 3
Nausea 8 10 0 0
Sensory neuropathy 6 8 0 0
Vomiting 9 11 0 0
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was 12 months (95% CI: 11–14 months) (Figure1). The 1-
and 2- year survival rates were 48% ( 95% CI: 37%–59%)
and 20% (95% CI: 11%–29%).
DISCUSSION
Although potentially curable when confined to one
hemithorax, SCLC with evidence of extrathoracic spread
(ES) has remained a frustrating enigma to clinicians in the
more than 20 years since cisplatin and etoposide were estab-
lished as the standard of care. Numerous efforts have been
made to raise the therapeutic bar above the level achieved
with the platinum/etoposide doublet. One approach has been
to evaluate three drug combinations either building on the
platinum/etoposide foundation or evaluating two newer
agents in combination with a platinum agent. The current
study took the latter approach to study the three drug com-
bination TCT with G-CSF support.
This multi-institutional cooperative group trial has dem-
onstrated that the TCT regimen has encouraging activity with
acceptable toxicity when used as initial therapy in patients with
ES-SCLC. Overall objective response rate was 68%, the median
survival was 12 months, and 1-year survival rate was 48%. The
survival outcome in this SWOG trial compares very favorably
with that of our previous phase II experience with paclitaxel,
cisplatin, and etoposide with growth factor support (SWOG
9705).18 Ninety-nine patients with previously untreated ES-
SCLC were enrolled into S9705. Overall response was 57%
(48/84 patients). Median and 1-year survival rates were 11
months and 43%, respectively. Toxicity was appreciable with
six patients (7%) dying of treatment-related causes. Recently,
results from the intergroup trial (CALGB 9732) comparing
cisplatin and etoposide (PE) with PE combined with paclitaxel
(PET) were reported.19 Unfortunately, no advantage was noted
with the addition of paclitaxel. Median survival was 9.84 and
10.33 months ion the PE and PET arms, respectively.
The toxicity profile of TCT was reasonably favorable.
As expected, hematologic toxicity was the most prominent
adverse effect. Approximately one third of patients experi-
enced grade 4 neutropenia and approximately one half had
grade 3 thrombocytopenia with 11% of patients requiring
platelet transfusions. Nevertheless, febrile neutropenia was
uncommon (5% of patients) and treatment-related deaths
were infrequent (3%). This is in contrast to the experience of
CALGB 9732 in which treatment-related death rates were
2.4% and 6.5% in the PE and PET arms, respectively, despite
the routine use of G-CSF in the PET arm.
One other phase II trial has been reported that evaluated
the combination of paclitaxel, carboplatin and topotecan in
ES-SCLC.20 In contrast to the current study, median survival
was disappointing and a high rate of treatment-related deaths
was noted. Hainsworth et al.20 employed a regimen of pacli-
taxel 135 mg/m2 by 1-hour intravenous infusion on day 1,
carboplatin AUC 5 on day 1, and topotecan 0.75 mg/m2 on
days 1 to 3. This regimen was administered every 21 days for
four cycles. Patients achieving an objective response or stable
disease after four cycles of treatment then received three
courses of oral etoposide repeated at 21-day intervals. G-CSF
was not routinely employed. They treated 105 patients with
limited SCLC and ES-SCLC. Response rate and median
survival were 88% and 8.3 months, respectively, in patients
with extensive disease. Seven of 59 patients (12%) with
extensive stage disease experienced treatment-related deaths.
Of note, despite the higher rate of grade 5 toxicity, lower
doses of paclitaxel and topotecan and a shorter schedule of
topotecan (3 days) were employed compared to the current
study. Potential reasons for the discrepancy in fatal toxicities
between the Hainsworth et al. study and the current trial may
be the routine use of G-CSF and the “late” schedule (day 4)
for carboplatin and paclitaxel administration in the current
study based on the previous phase I trial data, indicating an
apparent schedule dependency for hematologic toxicity.
To date, no three-drug regimen has demonstrated de-
finitive superiority to a platinum-etoposide doublet in SCLC.
An inherent potential limitation of all three drug regimens
that combine myelosuppressive agents is the necessity for
dose attenuations despite the use of G-CSF. In addition to
CALGB 9732, two other randomized trials have evaluated
the three-drug combination of paclitaxel, a platinum ana-
logue, and etoposide in ES-SCLC. The Greek Lung Cancer
Cooperative Group compared cisplatin and etoposide with
(TEP) or without the addition of paclitaxel.21 Prophylactic
G-CSF was used in the TEP arm. The study closed prema-
turely because of excessive toxicity and mortality in the TEP
arm, with no differences in objective response rates or me-
dian survival times between the two regimens. The other trial
was conducted in Germany. Reck et al.22 randomized 614
patients with stage I–IV SCLC to receive either a combina-
tion of paclitaxel plus etoposide plus carboplatin (TEC) or
FIGURE 1. Overall survival for the 79 eligible patients.
TABLE 3. Treatment Outcome (n  74)
Response No. of Patients %
Overall 50 68 (56–78*)
Complete 9 12
Partial 41 55
Stable 1 1
Increasing disease 4 5
Early death 2 3
Assessment inadequate 17 23
*95% confidence interval.
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carboplatin combined with etoposide and vincristine (CEV).
G-CSF was not routinely employed. Although overall median
survival was superior in the TEC arm (12.7 versus 11.7
months), this benefit was limited to patients with limited
stage disease as survival in ES patients was identical in the
two arms. Toxic death rates were 3% and 3.7% in the CEV
and TEC arms, respectively. The results of these three trials
strongly suggest that the addition of paclitaxel to a platinum-
etoposide doublet confers only added toxicity without an
improvement in survival in ES-SCLC.
The most promising lead in recent years for improving
outcome in ES-SCLC has involved another topoisomerase I
inhibitor, irinotecan. In a small phase III trial conducted by
the Japan Cooperative Oncology Group (JCOG), median
survivals of 9.4 months and 12.8 months were noted for
patients with ES-SCLC receiving cisplatin and etopside (EP)
or cisplatin and irinotecan (IP), respectively.6 The trial was
closed prematurely based on the results of an interim analy-
sis. Two confirmatory trials have been conducted in the
United States. One trial7 has been completed and the other is
an ongoing effort being conducted by SWOG (S0124). In the
completed trial, the IP regimen was modified from the sched-
ule employed by the JCOG in an attempt to improve drug
delivery and reduce toxicity. No significant differences were
noted between the treatment arms in response rates, median
time to progression, or overall survival. Whether the failure to
confirm the superiority of IP over EP is a function of the
modified dose and schedule of IP should be determined by the
ongoing SWOG trial, which is employing the same schedule
used by the JCOG.
Attempting to build on the results of the JCOG study,
Sekine et al.23 evaluated, in a phase II setting, two different
schedules of a cisplatin, etoposide, and irinotecan combina-
tion in chemotherapy-naive ES-SCLC patients. The most
promising schedule included cisplatin 60 mg/m2 day 1; iri-
notecan 60 mg/m2 days 1, 8, and 15; and etoposide 50 mg/m2
days 1 to 3, with G-CSF support every 4 weeks for four
cycles. This regimen demonstrated a median survival of 12.9
months.
In conclusion, this multicenter phase II trial has dem-
onstrated that a combination of paclitaxel, carboplatin, and
topotecan combined with G-CSF support is an active and
reasonably well-tolerated regimen for the treatment of ES-
SCLC with an encouraging median survival. However, the
cumbersome administration schedule and requirement for the
use of growth factor to achieve this modest survival benefit
makes this regimen less attractive for future study and will
not be further studied by SWOG. Attempting to combine
targeted agents with chemotherapy doublets may be a more
productive path to pursue.
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